Published in final edited form as:

Cell Mol Life Sci. 2011 July ; 68(13): 2201–2213. doi:10.1007/s00018-011-0713-7.

Role of Host-Defence Peptides in Eye Diseases

Satya S. Kolar and Alison M. McDermott*

Abstract

The eye and its associated tissues including the lacrimal system and lids have evolved several defence mechanisms to prevent microbial invasion. Included among this armory are several host-defence peptides. These multifunctional molecules are being studied not only for their endogenous antimicrobial properties but also for their potential therapeutic effects. Here the current knowledge of host-defence peptide expression in the eye will be summarized. The role of these peptides in eye disease will be discussed with the primary focus being on infectious keratitis, inflammatory conditions including dry eye and wound healing. Finally the potential of using host-defence peptides and their mimetics/derivatives for the treatment and prevention of eye diseases is addressed.

Keywords

defensin; cathelicidin; keratitis; dry eye; contact lens

1. Expression and Distribution of Host-Defence Peptides in the Eye and Associated Structures

Several studies over the past 10 to 15 years have confirmed that, like many tissues in the body, the eye and its associated structures (lids and lacrimal system for example) express a variety of host-defence peptides (HDPs). Prior review articles have primarily focused on HDPs at the ocular surface, here current knowledge of their expression by related structures and internal components are also addressed. Figure 1 summarizes the current understanding of HDP distribution in the human eye. As can be readily seen, HDPs of the β -defensin (hBD) family and the cathelicidin LL-37 are commonly found. For details on the chemical characteristics, basic biology and general mechanisms of antimicrobial, immunomodulatory and other actions of these and other HDPs, the reader is referred to other articles in this volume and recent reviews [1-5].

1.1 Ocular Surface

The ocular surface comprises the cornea, conjunctiva and tear film. The cornea is the transparent window covering the pupil and provides the major refracting surface of the eye. The conjunctiva is a thin mucous membrane harbouring immune cells, which covers the sclera, the white tough covering of the eye. The tear film coats the entire exposed surface of the eye providing lubrication and protection.

A squamous epithelium forms the outermost layer of both the cornea and conjunctiva and these cells are known to express a number of HDPs in keeping with their role as a major barrier to invading organisms. Both corneal and conjunctival epithelial cells constitutively

*author for correspondence University of Houston College of Optometry 4901 Calhoun Road 505 J Davis Armistead Bldg Houston TX 77204-2020 713 743 1974 (phone) 713 743 2053 (fax) amcdermott@optometry.uh.edu.

express hBD-1, whereas expression of hBD-2 is variable with it being found in normal tissue only occasionally [6-11]. hBD-2 is found more frequently in infected/inflamed ocular surface tissue which is in keeping with *in vitro* studies with cultured corneal and conjunctival epithelial cells showing that bacterial products such as lipopolysaccharide (LPS) and pro-inflammatory cytokines such as interleukin (IL)-1 β upregulate hBD-2 expression [8, 10-17]. These ocular surface epithelial cells also constitutively express hBD-3, which some have found to be upregulated in response to cytokines [10-11, 17-18]. Expression of hBD-4 has also been investigated in a number of studies, and while its expression is common in cultured ocular surface cells, it was found only infrequently in actual tissue samples [17-19]. hBD-9 was also recently found to be expressed by corneal and conjunctival epithelial cells [20-21]. However, while expression of several other members of the β -defensin family has been sought, they appear not to be present [18-19].

Although members of the α -defensin family, human neutrophil peptides (HNP) -1, -2, -3, have been detected in the corneal stroma (the thick collagen layer that forms the bulk of the cornea), their source is the neutrophils infiltrating the cornea in response to inflammatory signals rather than the resident corneal cells themselves [22]. Other α -defensins, human defensin (HD)-5 and -6 were not present [7, 23].

LL-37, the sole member of the human cathelicidin family is also expressed by corneal and conjunctival epithelial cells [18, 24]. This peptide is derived from a larger precursor, hCAP-18, and like hBD-2, its expression is upregulated in response to bacterial challenge [15-16, 25]. LL-37 is also found in neutrophil granules [26] so recruitment of these cells to the ocular surface in response to inflammation/infection would be expected to contribute to an increase in local levels of LL-37 (and indeed possibly several other neutrophil derived antimicrobial molecules).

While defensins and LL-37 are the most widely studied of the ocular surface HDPs the expression of several other peptides and proteins with antimicrobial activity has been reported. These include liver expressed antimicrobial peptide (LEAP)-1 (also known as hepcidin) and LEAP-2 [18], although another study failed to detect these HDPs [19]. The antimicrobial phosphoprotein, statherin is also expressed (Steele *et al.* (2004) Invest Ophthalmol Vis Sci 49: e-abstract 3792), as are MIP-3 α and thymosin β -4 [19] and some "antimicrobial cytokines" such as CCL28 and CXCL-1 [27-29]. Psoriasin (S100A7) is constitutively expressed in cornea and conjunctival epithelial cells and its expression is upregulated in response to some bacterial products (Garreis *et al.* (2009) Invest Ophthalmol Vis Sci 50: e-abstract 5515). Most recently, Mohammed *et al.* 2011, reported the expression of RNase-7 in cornea and conjunctiva and observed its upregulation in response to IL-1 β [30]. It should be cautioned that some of these other molecules have only been reported at the mRNA level and so confirmation of their expression awaits experiments addressing protein levels. Further for many of these, while they have been shown to have antimicrobial activity, this is sometimes relatively weak activity and it is likely that contributing to innate defence is not their primary role at the ocular surface. They may however be more directly involved in other activities recently ascribed to HDPs such as immunomodulation.

Studies in laboratory animals also confirm the existence of HDPs at the ocular surface with mice expressing a range of corneal and conjunctival defensins as well as cathelin related antimicrobial peptide (CRAMP), the homologue of human LL-37 [17, 31-34]. However, care should be taken in extrapolating from mouse to human as mice have many more β -defensins than humans and equivalency in terms of numerical designation cannot be assumed, for example the mouse orthologue of hBD-3 is mBD-14 [35], not mBD-3.

The tear film is a complex structure comprising an outermost lipid layer to limit evaporation which overlays a mix of possibly over 500 different proteins, electrolytes and mucins, with the latter increasing in concentration toward the ocular surface and interacting with the glycocalyx of the superficial corneal and conjunctival epithelial cells so adhering the tears to the cells [36]. It has long been established that tears contain important antimicrobial molecules such as lysozyme, phospholipase A2 and lactoferrin [37]. Recent studies also show that HDPs are present. These may arise from the main and/or accessory lacrimal glands, ocular surface epithelial cells or come from neutrophils that are naturally found in the tears in small numbers particularly upon eye-opening [38]. α -Defensins HNP1-3, whose source is neutrophils, are present at low levels in normal human tears, and are increased after ocular surface surgery [7,39]. Recently the presence of hBD-2 and -3 has also been reported [17]. Again, here the levels were low, and were less than would be needed for antimicrobial activity based on the results of *in vitro* studies, but these samples were normal tears and it is possible that much higher levels may be seen in samples from patients with active infections (unfortunately such samples are very hard to come by). Preliminary reports have shown that tears contain psoriasin (Garreis *et al.* (2009) Invest Ophthalmol Vis Sci 50: e-abstract 5515) and the antifungal peptide Histatin 5 (Steele *et al.* (2002), Invest Ophthalmol Vis Sci 43: e-abstract 98) and most recently dermcidin was detected [40].

1.2 Internal Ocular Components

HDP expression by internal ocular structures has not been intensively studied. A study by Lehmann *et al.* revealed that most samples of human lens capsule (which surrounds the crystalline lens) and iris (the coloured part of the eye) expressed mRNA for hBD-1 but not hBD-2 [9]. hBD-1 message was also detected in ciliary body (a highly vascularised structure surrounding the ciliary muscle that is involved in aqueous humour production and anchors the lens via the zonular fibers) but again hBD-2, and also α -defensins HD-5 and -6, were absent [41]. Retinal pigment epithelium and ciliary body epithelial cell lines did not express hBD-1 or -2 at baseline but the latter was upregulated after cytokine treatment. Further, immunoblotting showed that while samples of both vitreous and aqueous humour were positive for hBD-1 (although levels were estimated to be quite low), no hBD-2 was present. These studies suggest that hBD-1 is constitutively expressed inside the eye, while hBD-2 is not normally present but may be expressed in response to inflammation. Elucidation of the specific roles of these HDPs inside the eye awaits further investigation but it was suggested, that owing to its broader spectrum of activity and higher potency, that hBD-2 is a stronger candidate for antimicrobial defence inside the eye than hBD-1 [41].

1.3 Associated Ocular Structures

A number of structures external to the eye are important for normal ocular function, including the main and accessory lacrimal glands which supply the bulk of the aqueous component of the tear film, the lacrimal drainage system which conducts tears away from the ocular surface and the eyelids which serve a protective role and have glands that supply some tear film constituents. Haynes *et al.* reported the presence of hBD-1 message in lacrimal gland, but hBD-2 and α -defensins HD-5 and -6 were not found [7]. The lacrimal sac and nasolacrimal duct are major components of the lacrimal drainage system and harbour mucosa associate lymphoid tissue. In keeping with this protective role they also express HDPs [42]. hBD-1 was detected in several samples of nasolacrimal duct epithelium obtained by biopsy from both healthy patients and those with dacryocystitis. hBD-2 on the other hand was only detected in dacryocystitis patients. HNP1-3 was also detectable, with infiltrating neutrophils being the source in both healthy and diseased tissue. Messenger RNA for defence proteins bactericidal/permeability-increasing protein and cationic antimicrobial protein-37 was present however that for HD-5 and -6 was not, and interestingly mRNA for hCAP-18, the precursor to LL-37 was absent too. Some of these data have recently been

confirmed and the studies extended to include hBD-3 and -4 [17]. hBD-4 was not found in lacrimal gland or nasolacrimal ducts, however hBD-3 protein could be detected by ELISA and immunostaining, although RT-PCR failed to detect any mRNA. The glands of Moll (also referred to as ciliary glands) are apocrine glands located at the margin of the eyelids and secrete lipid onto the lid, which becomes incorporated in to the tear film. Recently hBD-1 and -2 and LL-37 were detected in the secretory end-pieces of the glands and are presumed to protect the glands themselves from infection, with the material being released in to the gland lumen being protective in the ducts, eyelash shaft and ocular surface [43]. β -Defensin expression has also been observed in the glands of Moll in non-human primates [44] and in various glands of the porcine eyelid [45].

This brief overview reveals a broad expression of HDPs in ocular and related structures. The value of some studies is a little limited due to experiments being restricted to investigation of message rather than actual protein, also a number were conducted before the study of HDPs came in to vogue and the discovery of the extent of the HDP repertoire. Thus, it will be of interest to revisit the area of HDP expression in intra-ocular and associated tissues and extend these investigations to additional defensins such as hBD-9 and other HDPs. The expression of HDPs suggests their participation in maintaining normal ocular health and function through their antimicrobial action as well as any/all of the myriad of activities they have been found to perform in other tissues such as modulating immune responses and wound healing [3,46]. However, in the eye only defensins and cathelicidin have been studied in any depth and the focus of these investigations has been the ocular surface and in particular the cornea. Therefore, these particular HDPs and this location form the basis for the following discussions on the role of endogenously expressed HDPs in eye diseases and their clinical potential as ocular therapeutics.

2. Role for Endogenous Host-Defence Peptides in Eye Diseases

2.1 Defence Against Infection

The majority of studies investigating the role of HDPs in preventing ocular infection have focused on microbial keratitis. This affects the cornea, the primary refracting surface of the eye, and if not treated promptly and adequately may result in permanent vision loss. Microbial keratitis may be caused by bacteria, viruses, fungi and protozoa with contact lens wear and corneal trauma being common risk factors.

Pseudomonas aeruginosa and *Staphylococcus aureus* are two of the most common causes of bacterial keratitis with *P.aeruginosa* being the most common cause in contact lens wearers [47,48]. *P.aeruginosa* is a particularly dangerous and dreaded ocular pathogen and induces very severe disease, which, if not quickly treated or if unresponsive to treatment, rapidly progresses to inflammation, neovascularisation and liquefactive necrosis of the cornea. As discussed above (section 1.1) ocular surface epithelial cells express defensins and the cathelicidin LL-37 and infection, and exposure to bacterial products *in vitro* increases expression of some of these, although in contrast hBD-9 is decreased in infection [6-12, 15-17, 20]. Ocular surface expressed HDPs are also active, to varying degrees, against common ocular bacterial pathogens [19,24]. hBD-1 is the least effective defensin having relatively moderate antimicrobial activity against *P. aeruginosa* but being poorly effective against *Staphylococcal* strains. hBD2 has good antimicrobial activity against *P. aeruginosa* although its activity towards *S.aureus* is limited. hBD3 and LL37 on the other hand have good bactericidal activity against both *P. aeruginosa* and *S. aureus*. The level of HDPs detected *in vivo* and cultured cells is generally much lower than is required for antimicrobial activity *in vitro*. For example, Zhou *et al.* reported that normal tear film levels of HNPs are in the range 0.2 to 1 $\mu\text{g/ml}$ and rise to a maximum of 20 $\mu\text{g/ml}$ after ocular surgery [39]. This latter level would be expected to result in mild to at best, moderate antibacterial activity

depending on the target strain. Garreis *et al.* recently quantitated levels of hBD-2 and hBD-3 in human cornea, conjunctiva, lacrimal gland and tears [17]. The peptides were present at picogram amounts and highest levels were in the cornea. Unpublished data from our laboratory also shows hBD-2 to be present in normal tear fluid at 329+/- 154 pg/ml. These levels are far below those required for antibacterial activity *in vitro*, but it should be noted they are reflective of the normal ocular surface and levels would be expected to rise somewhat in response to infection. However, *in vitro* HDPs show effective antibacterial activity at concentrations of several µg/ml and above and so it is questionable that such high amounts are actually present at the ocular surface *in vivo* even after induction by pathogens. Rather, as has been suggested for other tissues [49,50], within the environment of the tear film and epithelial layer as yet undefined mechanisms are likely to exist to raise the local concentration of HDPs to effective levels.

It has long been recognized, that because of their mode of antibacterial action, i.e. electrostatic interaction with negatively microbial membranes, cationic HDPs are subject to varying degrees of sensitivity to physiological salt concentrations [3]. This is of particular concern at the ocular surface, which is bathed in tear fluid. Huang *et al.* investigated the antibacterial activity of various HDPs expressed by ocular surface epithelial cells in the presence of human tears and observed that activity of hBD-1 and hBD-2 was markedly reduced, whereas that for hBD-3 and LL-37 was much less affected [19,25]. Furthermore, while some of the loss of activity was attributable to salt effects, MUC5AC, the major gel forming mucin of the tear film, was also found to inhibit the anti-pseudomonal activity of hBD-2 [51]. Together, these current *in vitro* findings suggest that at the human ocular surface *in vivo*, hBD-3 and LL-37 are the HDPs most likely to have significant independent antibacterial activity. Others such as hBD-1, hBD-2 and HNP1-3 may have roles to play under circumstances when high concentrations can be achieved or when they can interact synergistically with other HDPs and antimicrobial molecules as both situations would be expected to help temper the effects of high salt and perhaps that of other interfering tear film components [52-54].

A number of animal studies provide compelling evidence to support a role for HDPs in defence against *P. aeruginosa* infection at the ocular surface. Huang *et al.* showed that mice deficient in CRAMP, the murine homologue of LL-37, have increased susceptibility to bacterial keratitis as manifest by delayed *P. aeruginosa* clearance, increased numbers of neutrophils, an altered cytokine profile and worse clinical score [31]. Subsequently, roles for some defensins have also been revealed, as mice in which expression of mBD-2 or mBD-3 (an orthologue of hBD-2), but not mBD-1 or mBD-4, was knocked down with siRNA also showed increased susceptibility to *P. aeruginosa* infection [33,34]. Further, flagellin pre-treatment has been found to reduce inflammation and improve clinical outcome in experimental murine *P. aeruginosa* keratitis, an effect that, at least in part, was attributable to the upregulation of antimicrobial molecules including CRAMP [55]. In these afore mentioned models the cornea is scratched to facilitate infection. A recent study by Augustin *et al.* shows that the un-scratched ocular surface of mice deficient in mBD-3 has reduced capacity to clear *P. aeruginosa* and increased susceptibility to colonization, indicating for the first time that HDPs are important in prevention of bacterial keratitis, and not just after the infection has been initiated [56]. Thus, while more in depth investigation is required to fully understand the role of specific HDPs in bacterial keratitis in humans, animal models conclusively show that despite potential confounding factors of low concentrations and interference from tear film components, HDPs do function to defend the cornea against *P. aeruginosa* infection.

The role of HDPs in other forms of microbial keratitis has not yet been investigated in depth. Herpes simplex virus (HSV) and adenovirus are two common ocular viral pathogens. There

are some 20,000 new cases of ocular HSV infection in the USA each year and, owing to viral latency, an additional 28,000 reactivations [57]. Infection can lead to a very robust inflammatory response with the formation of classic dendritic corneal ulcers making HSV keratitis the most frequent cause of corneal blindness in the USA. Adenoviruses are the most common cause of viral conjunctivitis and keratoconjunctivitis. While typically not as serious as HSV keratitis, these infections are highly contagious and cause significant morbidity and discomfort. Despite the serious nature and frequency of viral infections, a role for HDPs has not been investigated. It is known however that α -defensins and LL-37 have activity against both HSV-1 and adenoviridae *in vitro* suggesting they may be active against these pathogens *in vivo* [24,58,59].

Fungi are a significant cause of keratitis particularly in warm humid climates and developing countries where they may account for 40% or more of microbial keratitis cases [48, 60-63]. Common culprits are *Fusarium solani*, *Aspergillus fumigatus* and *Candida albicans* [61,63-68]. These infections are very difficult to treat and are characterized by corneal edema and ulceration leading to scarring, and profound vision loss. That various HDPs have activity against a range of fungi is well established and fungi have been shown to modulate the expression of HDPs in a variety of epithelial cells [69-83]. However mice deficient in CRAMP, the homologue of LL-37, did not show increased susceptibility to *C. albicans* in an intradermal infection model, leading the authors to conclude that cathelicidins may be most effective as a superficial barrier to infection [74]. Recent studies have started to address a role for HDPs in fungal keratitis. Yuan *et al.* investigated the expression of various HDPs in a mouse model of *Candida* keratitis and found that CRAMP was markedly increased in response to the infection [84]. Further, Gao *et al.* have shown that mice deficient in CRAMP have more severe *Candida* keratitis than wild type mice [85]. These positive results in comparison to the earlier study of Lopez-Garcia *et al.* in a skin model of *C. albicans* infection [74] may reflect the more “superficial”/mucosal nature of the corneal infection [85]. Overall, these studies indicate a potential role for LL-37 in particular, but possibly also other HDPs, in preventing/limiting fungal keratitis in humans.

Acanthamoeba keratitis is relatively uncommon, but is of interest as there was a recent outbreak of *A. castellanii* keratitis associated with a particular contact lens solution [86]. An early study investigated amphibian magainins and found them to have activity against the trophic and cystic stages of *A. polyphaga* [87]. More recently Otri *et al.* have observed that *A. castellanii* stimulated the expression of several HDPs including hBD-3 and LL-37 in cultured corneo-limbal epithelial cells but decreased expression of hBD-1 [88]. Together these studies suggest that HDPs may play a role in the innate response to *Acanthamoeba* keratitis but this needs to be investigated further.

That external risk factors such as contact lens wear and trauma pre-dispose an individual to corneal infection are well established. The issues relating contact lens wear to infection are complex and currently patient compliance with cleaning routines is an area of intense study. Interesting results from a recent *in vitro* study also reveal additional novel avenues for investigation [89]. Here it was found that contact lenses impaired the ability of human corneal epithelial cells to secrete hBD-2 in response to exposure to *P. aeruginosa* antigens, implying that lens wear per-se may interfere with the ocular surface HDP innate response. Also, little is known about individual genetic variation in the host response that increases susceptibility to corneal infection. Recent research suggests copy number variation and/or polymorphisms in HDP genes (defensins in particular) contribute to susceptibility to infection and may underlie the onset of chronic inflammatory diseases such as psoriasis and Crohn's disease [90-92]. Interestingly, Carter *et al.* reported a case of bilateral endophthalmitis associated with the hBD-1 genotype -44CC, an allele previously shown to be associated with a predisposition to infection [93]. Endophthalmitis is a rare complication

of cataract surgery. Most cases are due to infection and result in vision threatening inflammation of the intraocular cavities. A subsequent study by the same group with a larger patient cohort, showed the -44CC genotype to be more common in patients who have had endophthalmitis suggesting a potential genetic risk factor that reduces innate immune defences in this intra-ocular infection [94]. An association between such genetic variations and microbial keratitis has not yet been investigated but could provide novel insight in to an individuals' pre-disposition to infection that could be incorporated into a genome based approach to treatment in which care (e.g. the recommendation to wear contact lenses or not) is tailored to individuals based on their specific-genetic make-up.

2.2 Inflammatory Conditions

Dry eye syndrome is a very common ocular surface condition resulting from decreased tear secretion or increased tear evaporation and is one of the leading causes for visits to an eye doctor [95]. It is a multifactorial condition in which inflammation plays a major role. Tear fluid hyperosmolality and tear film instability stimulate an increase in pro-inflammatory cytokines and the resulting inflammation further exacerbates the response leading to damage to the ocular surface and symptoms of dryness, irritation and pain [96-101]. We observed that hBD-2 was specifically upregulated in the conjunctiva of patients with dry eye [11]. This was also confirmed in patients with Sjogren's syndrome, which results in a very severe form of dry eye due to autoimmune destruction of the lacrimal gland [102]. Pro-inflammatory cytokines IL-1 β and TNF α are known to be elevated in dry eye and were able to stimulate hBD-2 expression in human conjunctival epithelial cells in culture leading to the suggestion that they may be responsible for the elevated expression in dry eye patients [11]. However, when this was investigated further, a hyperosmolar culture environment was actually found to blunt IL-1 β stimulation of hBD-2 production [103] suggesting that this cytokine may not have a major role to play in modulating ocular surface hBD-2 expression in dry eye. Interestingly, while hBD-1 and -3 were unchanged and hBD-2 upregulated in patients with dry eye, another defensin, hBD-9 was found to be decreased [20]. Murine models have been important in elucidating the mechanisms underlying dry eye, however when defensin expression was examined in the cornea and conjunctiva of mice with experimental dry eye the changes compared to normal mice were not dramatic [32]. Thus, the mechanisms underlying modulated defensin expression in dry eye have yet to be established. Further, the specific role of these HDPs in dry eye is also still a subject for investigation. That enhanced expression of hBD-2 will give additional antimicrobial protection is a logical speculation and is in keeping with observations that dry eye patients (with the exception perhaps of those with Sjogren's syndrome [104]) do not commonly present with infection despite having a disrupted ocular surface. On the other hand, hBD-9 is not expected to have a major antimicrobial effect, therefore its reduced expression in dry eye is not likely to compromise innate immunity [20]. HDPs are of course known to have a wide range of activities in addition to their antimicrobial actions thus their altered expression in dry eye may influence several aspects of the disease process for example through their chemotactic effects they may help mediate T cell recruitment [105].

Hida *et al.* found that α -defensins were elevated in the tears of patients with ocular allergies complicated by the presence of corneal lesions and speculated that this may help prevent secondary infection in these patients [106]. However, as the elevated levels were only seen in patients with lesions, this observation appears to be linked to corneal injury (discussed in section 2.3 below) rather than the allergic response per-se. Ikeda *et al.* noted that mRNA expression for mBD-1 was unchanged but that of mBD-2 was decreased compared to normal mice in a model of allergic conjunctivitis [107]. The authors note that patients with ocular allergies are susceptible to infection and extrapolate from their findings to suggest that this may be associated with reduced hBD-2 expression. However as mBD-2 does not

appear to be an orthologue of hBD-2 the ultimate significance of the findings in this mouse model are unknown.

An early-discovered property of LL-37 is that it binds and inactivates LPS, a component of the cell wall of Gram-negative bacteria that stimulates a strong inflammatory response through activation of TLR4 [108,109]. Thus, endogenously expressed LL-37 may actually help reduce ocular inflammation associated with bacterial infection. Ohgami *et al.* reported that hCAP-18 (the LL-37 precursor) suppressed the acute inflammatory response in a rat model of LPS induced uveitis and suggested that this peptide may be a promising agent for the treatment of inflammation [110]. Interestingly, Jager *et al.* recently detected the presence of cationic amino acid transporters at the ocular surface and lacrimal apparatus and suggested there is a functional relationship between them and β -defensins in a regulatory circuit via which the balance toward β -defensin production could be shifted to treat atopic and inflammatory diseases [111,112]. An alternative role for endogenous HDPs, although one that has yet to be investigated, is that some may actually exacerbate an inflammatory response so contributing to disease processes. This may be mediated through HDP cytotoxic effects (cytotoxic levels may be reached for peptides whose expression is upregulated by pro-inflammatory cytokines), ability to induce mast cell degranulation [113,114] and influence cytokine secretion [25, 115-118] and leukocyte migration [119-121].

2.3 Wound Healing

The most commonly studied ocular tissue in terms of wound healing is the ocular surface, in particular the cornea. This is because rapid healing of the cornea is essential to restore a smooth surface for refraction of light and barrier function to prevent pathogen penetration, which may otherwise lead to fulminant infection and permanent vision loss. Studies carried out over more than two decades have shown a substantial redundancy in terms of endogenous factors capable of modulating wound healing at the ocular surface, a testament to the importance of having healing happen rapidly and effectively [122]. Recent studies provide evidence that HDPs may also contribute to these processes.

The expression of some HDPs, such as hBD-2 and LL-37, is increased and neutrophils, a source of α -defensins and LL-37, are known to infiltrate the cornea after injury [25, 123]. Notably several studies have found that these HDPs can modulate activities such as migration, proliferation and cytokine production, all of which are essential for accurate and timely ocular surface healing [122]. For example, through activation of formyl peptide receptor-like 1 and transactivation of the epidermal growth factor receptor, LL-37 stimulated migration and cytokine secretion by corneal epithelial cells [25]. Notably, LL-37 also promoted wound closure in a corneal epithelial cell monolayer scratch model and promoted healing in a corneal organ culture model in which a high glucose environment was used to slow healing so mimicking the delayed corneal re-epithelialization seen in diabetic patients [124]. Further, HNP-1, hBD-2 and hBD-3 were found to stimulate cytokine production by conjunctival epithelial cells, and HNP-1 and hBD-2 enhanced proliferation, collagen gene expression and modulated matrix metalloproteinase production by conjunctival fibroblasts [125,126]. Overall these findings support a role for defensins and LL-37 in modulating cell migration and proliferation during corneal wound healing and tissue remodeling, effects that may be direct receptor mediated actions or indirect via cytokine production. In most tissues, neovascularisation is an important component of wound healing. However, the development of new blood vessels in the cornea reduces corneal transparency resulting in visual dysfunction. It is of significance therefore, that while LL-37 is pro-angiogenic, HNPs are anti-angiogenic [127-129]. Thus, the relative levels of LL-37 (from epithelial cells and infiltrating neutrophils) and HNPs (from infiltrating neutrophils) may contribute to maintaining corneal avascularity after injury. Although not tested at the ocular surface, HNPs inhibited neovascularisation in the retina, another ocular tissue in which pathological

vessel growth in conditions such as diabetic retinopathy can lead to profound visual loss, even blindness [129].

That endogenously expressed peptides can influence and stimulate the various cell behaviours important for wound healing at the ocular surface also suggests that HDPs or their derivatives/mimetics may be useful as topical agents to promote corneal healing responses in diseases such as diabetes and following accidental injury or elective procedures such as refractive surgeries that involve damage to the ocular surface.

3. Host-Defence Peptides as Therapeutics for Eye Diseases

To date the majority of studies of HDPs as potential therapeutics for eye diseases have focused on their anti-infective properties for microbial keratitis. As discussed earlier (section 2.1) this affects the cornea, the major refracting surface of the eye, and if not adequately and rapidly treated may result in permanent loss of vision. As is the case in many infectious diseases, the emergence of resistant strains is a growing issue in the treatment of microbial keratitis and is driving the search for novel antimicrobial agents. As discussed by others, through their mechanism of action, HDPs have reduced potential for development of resistance [130], thus several studies have investigated the potential of using HDPs or their derivatives/mimetics in a variety of therapeutic paradigms for treating or preventing corneal infection.

3.1 Topical Application

Ease of access to the cornea makes it an ideal candidate for topical drug application and there have been a small number of studies investigating HDP efficacy in animal models of microbial keratitis. Employing synthetic peptides containing partial sequences from cecropin A (an insect peptide) and melittin (from bee venom), Nos-Barbera *et al.* noted reduced inflammation and less corneal damage compared to vehicle control in a rabbit model of *P. aeruginosa* keratitis [131]. Also, retrocyclin 2, a synthetic Θ -defensin, had anti-viral activity in a murine model of HSV-1 keratitis when given prophylactically, although not when administered for an established infection [132]. However, in contrast to these, at least somewhat successful studies, a synthetic peptide COL-1, which had potent antimicrobial activity *in vitro*, did not show a clinical benefit in a rabbit model of *P. aeruginosa* keratitis. Rather the peptide treated animals showed more inflammation than controls [133]. This latter study highlights two major issues, namely lack of efficacy and toxicity. Although the reason for the lack of effect with COL-1 is not known, it is possible that it may have been the result of inactivation of the peptide by components in the tear film. Studies have shown that tears do interfere with the antimicrobial activity of some HDPs [19,25,134]. Also as discussed earlier (section 2.1) while this is in part attributable to the salt content of tears, MUC5AC also dramatically reduced the activity of hBD-2 against *P. aeruginosa* [51]. Notably tears, over and above the effects of salt, also inhibited the antibacterial activity of hBD-1 whereas hBD-3 and LL-37 were substantially less affected [19,25]. These observations highlight the need for thorough investigation in to the potential detrimental effects of tears on HDP activity before embarking on *in vivo* studies. We also observed that various artificial tear solutions also reduced HDP antimicrobial activity [135]. This is of some concern as these over the counter preparations are commonly used to relieve the symptoms of dry eye and patients may inadvertently be suppressing the innate response so increasing their risk for ocular infection. Another issue with the use of HDPs as ocular therapeutics is toxicity. Although HDPs show selectivity for microbial membranes, for some peptides, this is lost at higher concentrations and they become toxic to mammalian cells [3]. This is an obvious issue as high peptide concentrations may be warranted to overcome the effects of interfering entities such as tear film salt and mucins. Recent studies have shown that lowering the hydrophobicity of linear hBD-3 analogues reduces cytotoxicity to ocular

surface epithelial cells while maintaining antimicrobial efficacy, so revealing one possible approach to overcoming the toxicity issue [136,137]. Covalent dimerization and multivalent forms of HDPs are a further strategy to help address issues such as cytotoxicity [138]. We have observed that tethering of a HDP (in our case a derivative of the cathelicidin LL-37) to a “surface” greatly enhances its efficacy against ocular pathogens compared to peptide in solution [139, Qin G *et al.* (2008) Invest. Ophthalmol. Vis. Sci. e-abstract #4790; McDermott AM *et al.* (2010) Invest. Ophthalmol. Vis. Sci. e-abstract #3433]. Thus, we believe that attachment of a HDP to a surface (such as a contact lens as described in section 3.3) or a nanoparticle scaffold such as a liposome or dendrimer is much more likely to result in potent non-cytotoxic antimicrobial activity at the ocular surface than simply applying the peptide in solution and so represents a very promising mode of delivery.

3.2 Corneal Preservation Media and Contact Lens Care Solutions

Corneal transplants are the most common and most successful solid tissue transplant performed in the US, with more than 40,000 being performed per year. After removal from the donor the tissue is placed in to a preservation medium, which helps prevent bacterial growth while the cornea is in storage at 4°C until it is used for transplantation. Again, the spread of organisms resistant to the traditional antibacterial agents contained within these preservation media has lead to a search for alternative components. Schwab *et al.* tested defensin antimicrobial activity against common ocular pathogenic bacteria in the corneal preservation medium Optisol™ and found them to be effective at 4°C so revealing their potential as preservatives for corneal storage [140]. In a related study, the bovine peptide BNP-1 was found to help preserve endothelial cell (essential for normal corneal transparency) viability in stored corneas (Reid *et al.* (1998) Invest Ophthalmol Vis Sci 39: e-abstract 358). Thus, HDPs, when added to corneal storage media may have dual benefits. Notably, BNP-1 as part of a mix of trophic factors has also been found to improve kidney preservation [141].

As noted previously, contact lens wear is a major risk factor for the development of microbial keratitis, particularly that caused by *P. aeruginosa*. An important factor in minimizing this risk is adequate disinfection of the lenses during cleaning and overnight storage. Cecropin D5C, a synthetic insect antimicrobial peptide, has been shown to augment the antimicrobial activity of contact lens solutions against *P. aeruginosa* so supporting a potential use of HDPs as effective contact lens disinfectants [142]. The mid-2000s saw outbreaks of both *Fusarium* and *Acanthamoeba* keratitis related to contact lens-wear and use of specific contact lens solutions, highlighting the need for improved contact lens hygiene practices and contact lens disinfectant test regimens [86]. Notably, a number of HDPs have potent anti-fungal activity [69-77] and the amphibian peptide magainin has been found to have activity against *Acanthamoeba* [87] thus, they may be useful as novel disinfectants for elimination of potentially vision threatening pathogens such as *Fusarium* and *Acanthamoeba*.

One potential factor limiting the use of HDPs in these sorts of clinical applications is that relatively large volumes would be required and this is likely to be prohibitively expensive. It may however be possible to circumvent some of this cost by tethering a HDP to a nanoparticle so enhancing its efficacy and reducing the amount of peptide needed and/or using the shortest peptide sequence required for optimal antimicrobial activity.

3.3 Antimicrobial Contact Lenses

As contact lens wear is associated with increased risk for corneal infection there has been significant interest in the development of contact lenses with antimicrobial, and specifically anti-pseudomonal, properties. Contact lens associated microbial keratitis is the result of

colonization of the lens surface which then leads to contamination of the cornea upon insertion of the lens in to the eye. Thus, major efforts are being directed toward development of lenses, which prevent bacterial adherence and biofilm formation. Many potential agents have been investigated but development of microbial resistance is an issue as is loss of activity after covalent attachment, inability to sterilize the lenses after attachment of the antimicrobial and toxicity to ocular surface cells. Nevertheless, some agents have been identified that hold particular promise and those currently under investigation include selenium [143], quorum-sensing inhibitors such as fimbrolides [144] and antimicrobial peptides [145,146]. In regards to the latter, Willcox *et al.* developed a synthetic cationic peptide termed melimine which combined active, but minimally cytotoxic, sequences from mellitin (from bee venom) and protamine (from salmon sperm). This hybrid peptide when adsorbed or covalently linked to contact lenses, reduced colonization by *P. aeruginosa* and *S. aureus* by 70-80% [145]. Notably, melimine did not induce resistance after repeated exposure of the organisms to sub-inhibitory concentrations of the peptide and was heat-stable. Subsequently, the effectiveness of melimine covalently incorporated in to silicone hydrogel lenses was tested in animal models *in vivo* [146]. In a guinea pig model of contact lens acute red eye induced by *P. aeruginosa*, animals fitted with melimine-coated lenses had significantly less ocular inflammation, chemosis and discharge compared to animals fitted with control lenses. Corneal infiltrates were also markedly reduced. Similarly, melimine coated-lenses performed favourably in a rabbit model of contact lens-induced peripheral ulcer caused by *S. aureus*. Here rabbits fitted with the melimine coated-lenses had significantly lower scores for ocular inflammation and a threefold reduction in the presence of a corneal epithelial defect compared to those wearing control lenses. These studies highlight the potential of HDPs and derivatives thereof as coatings for antimicrobial contact lenses. Also it is encouraging that, although no antimicrobial contact lens has yet been approved, in a very closely related arena, antimicrobial contact lens cases, which exploit the antibacterial activity of the well-known biocide silver, are now on the market.

Summary

In summary, eye and associated tissues such as the lacrimal apparatus express a range of HDPs which help prevent infection and are likely involved in wound healing responses and tissue remodeling. These endogenous HDPs may also be involved in ocular inflammatory and immune responses although much remains to be discovered about such roles. Development of a HDP or derivative/mimic thereof for therapeutic purposes is an attractive proposition, and because of ease of application (topical or local injection), which reduces some of the confounding factors associated with systemic delivery, is indeed a viable option.

Acknowledgments

The authors thank Ms. Kimberly Thompson of the University of Houston, College of Optometry Audio Visual Services for drawing figure 1. The authors' research on HDPs in the eye is supported by grants from the National Eye Institute (EY13175, EY7551) and collaborative grants with Dr. C. Cai awarded by the National Science Foundation (DMR-0706627) and National Eye Institute (EY18303).

Abbreviations

HDP	host-defence peptide
hBD	human β -defensin
mBD	mouse β -defensin
HNP	human neutrophil peptide

LL-37	human cathelicidin
CRAMP	cathelin related antimicrobial peptide
LPS	lipopolysaccharide

References

1. Hale JD, Hancock RE. Alternative mechanisms of action of cationic antimicrobial peptides on bacteria. *Expert Rev Anti Infect Ther.* 2007; 5:951–959. [PubMed: 18039080]
2. Radek K, Gallo R. Antimicrobial peptides: natural effectors of the innate immune system. *Semin Immunopathol.* 2007; 29:27–43. [PubMed: 17621952]
3. McDermott, AM. Antimicrobial peptides. In: Howl, J.; Jones, S., editors. *Bioactive Peptides*. CRC Press; Boca Raton: 2009.
4. Nijnik A, Hancock RE. The roles of cathelicidin LL-37 in immune defences and novel clinical applications. *Curr Opin Hematol.* 2009; 16:41–47. [PubMed: 19068548]
5. Steinsraesser L, Kraneburg U, Jacobsen F, Al-Benna S. Host defense peptides and their antimicrobial-immunomodulatory duality. *Immunobiology.* Aug 19.2011 2010 ePub ahead of print.
6. Hattenbach LO, Gumbel H, Kippenberger S. Identification of beta-defensins in human conjunctiva. *Antimicrob Agents Chemother.* 1998; 42:3332. [PubMed: 10049242]
7. Haynes RJ, Tighe PJ, Dua HS. Antimicrobial defensin peptides of the human ocular surface. *Br J Ophthalmol.* 1999; 83:737–741. [PubMed: 10340986]
8. McNamara NA, Van R, Tuchin OS, Fleiszig SMJ. Ocular surface epithelia express mRNA for human beta defensin-2. *Exp Eye Res.* 1999; 69:483–490. [PubMed: 10548468]
9. Lehmann OJ, Hussain IR, Watt PJ. Investigation of β -defensin gene expression in the ocular anterior segment by semiquantitative RT-PCR. *Br J Ophthalmol.* 2000; 84:523–526. [PubMed: 10781518]
10. McDermott AM, Redfern RL, Zhang B, Pei Y, Huang L, Proske RJ. Defensin expression by the cornea: multiple signaling pathways mediate IL-1 β stimulation of hBD-2 expression by corneal epithelial cells. *Invest Ophthalmol Vis Sci.* 2003; 44:1859–1865. [PubMed: 12714616]
11. Narayanan S, Miller WL, McDermott AM. Expression of human beta-defensins in conjunctival epithelium: relevance to dry eye disease. *Invest Ophthalmol Vis Sci.* 2003; 44:3795–3801. [PubMed: 12939294]
12. Kumar A, Zhang J, Yu FS. Innate immune response of corneal epithelial cells to staphylococcus aureus infections: role of peptidoglycan in stimulating proinflammatory cytokine secretion. *Invest Ophthalmol Vis Sci.* 2004; 45:3513–3522. [PubMed: 15452057]
13. Shin JS, Kim CW, Kwon YS, Kim JC. Human beta-defensin 2 is induced by interleukin-1 β in the corneal epithelial cells. *Exp Mol Med.* 2004; 36:204–210. [PubMed: 15272231]
14. Kumar A, Zhang J, Yu FS. Toll-like receptor 2-mediated expression of beta-defensin-2 in human corneal epithelial cells. *Microbes Infect.* 2006; 8:380–389. [PubMed: 16242370]
15. Kumar A, Yin J, Zhang J, Yu F-SX. Modulation of corneal epithelial innate immune response to *Pseudomonas* infection by flagellin pretreatment. *Invest Ophthalmol Vis Sci.* 2007; 48:4664–4670. [PubMed: 17898290]
16. Li Q, Kumar A, Gui JF, Yu FS. *Staphylococcus aureus* lipoproteins trigger human corneal epithelial innate response through toll-like receptor-2. *Microb Pathog.* 2008; 44:426–434. [PubMed: 18191935]
17. Garreis F, Schlorf T, Worlitzsch D, Steven P, Bräuer L, Jäger K, Paulsen FP. Roles of human beta-defensins in innate immune defense at the ocular surface: arming and alarming corneal and conjunctival epithelial cells. *Histochem Cell Biol.* 2010; 134:59–73. [PubMed: 20526610]
18. McIntosh RS, Cade JE, Al-Abed M, Shanmuganathan V, Gupta R, Bhan A, Tighe PJ, Dua HS. The spectrum of antimicrobial peptide expression at the ocular surface. *Invest Ophthalmol Vis Sci.* 2005; 46:1379–1385. [PubMed: 15790905]

19. Huang LC, Jean D, Proske RJ, Reins RY, McDermott AM. Ocular surface expression and in vitro activity of antimicrobial peptides. *Curr Eye Res.* 2007; 32:595–609. [PubMed: 17852183]
20. Abedin A, Mohammed I, Hopkinson A, Dua HS. A novel antimicrobial peptide on the ocular surface shows decreased expression in inflammation and infection. *Invest Ophthalmol Vis Sci.* 2008; 49:28–33. [PubMed: 18172071]
21. Mohammed I, Suleman H, Otri A, Kulkarni BB, Chen P, Hopkinson A, Dua HS. Localization and gene expression of human β -defensin 9 at the human ocular surface epithelium. *Invest Ophthalmol Vis Sci.* 2010; 51:4677–4682. [PubMed: 20375350]
22. Gottsch JD, Li Q, Ashraf MF, O'Brien TP, Stark WJ, Liu SH. Defensin gene expression in the cornea. *Curr Eye Res.* 1998; 17:1082–1086. [PubMed: 9846627]
23. Haynes RJ, Tighe PJ, Dua HS. Innate defence of the eye by antimicrobial defensin peptides. *Lancet.* 1998; 352:451–452. [PubMed: 9708756]
24. Gordon YJ, Huang LC, Romanowski EG, Yates KA, Proske RJ, McDermott AM. Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. *Curr Eye Res.* 2005; 30:1–10. [PubMed: 15875358]
25. Huang LC, Petkova TD, Reins RY, Proske RJ, McDermott AM. Multifunctional roles of human cathelicidin (LL-37) at the ocular surface. *Invest Ophthalmol Vis Sci.* 2006; 47:2369–80. [PubMed: 16723446]
26. Sorensen O, Arnljots K, Cowland JB, Bainton DF, Borregaard N. The human antibacterial cathelicidin, hCAP18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. *Blood.* 1997; 90:2796–2803. [PubMed: 9326247]
27. Cole AM, Ganz T, Liese AM, Burdick MD, Liu L, Strieter RM. Cutting edge: IFN-inducible ELR-CXC chemokines display defensin-like antimicrobial activity. *J Immunol.* 2001; 167:623–627. [PubMed: 11441062]
28. Yang D, Chen Q, Hoover DM, Staley P, Tucker KD, Lubkowski J, Oppenheim JJ. Many chemokines including CCL20/MIP-3 α display antimicrobial activity. *J Leukoc Biol.* 2003; 74:448–455. [PubMed: 12949249]
29. Spandau UH, Toksoy A, Verhaart S, Gillitzer R, Kruse FE. High expression of chemokines Gro- α (CXCL-1), IL-8 (CXCL-8), and MCP-1 (CCL-2) in inflamed human corneas in vivo. *Arch Ophthalmol.* 2003; 121:825–831. [PubMed: 12796254]
30. Mohammed I, Yeung A, Abedin A, Hopkinson A, Dua HA. Signalling pathways involved in ribonuclease-7 expression. *Cell Mol Life Sci.* 2011 In press.
31. Huang LC, Reins RY, Gallo RL, McDermott AM. Cathelicidin-deficient (Cnlp $^{-/-}$) mice show increased susceptibility to *Pseudomonas aeruginosa* keratitis. *Invest Ophthalmol Vis Sci.* 2007; 48:4498–4508. [PubMed: 17898271]
32. Narayanan S, Corrales RM, Farley W, McDermott AM, Pflugfelder SC. Interleukin-1 receptor-1-deficient mice show attenuated production of ocular surface inflammatory cytokines in experimental dry eye. *Cornea.* 2008; 27:811–817. [PubMed: 18650668]
33. Wu M, McClellan SA, Barrett RP, Hazlett LD. Beta-defensin-2 promotes resistance against infection with *P. aeruginosa*. *J Immunol.* 2009; 182:1609–1616. [PubMed: 19155510]
34. Wu M, McClellan SA, Barrett RP, Zhang Y, Hazlett LD. Beta-defensin-2 and 3 together promote resistance to *Pseudomonas aeruginosa* keratitis. *J Immunol.* 2009; 183:8054–8060. [PubMed: 19933858]
35. Hinrichsen K, Podschun R, Schubert S, Schroder JM, Harder J, Proksch E. Mouse beta-defensin-14, an antimicrobial ortholog of human beta-defensin-3. *Antimicrob Agents Chemother.* 2008; 52:1876–1879. [PubMed: 18332171]
36. Tsubota, K. Tear film overview. In: Dartt, DA., editor. *Encyclopedia of the Eye.* Elsevier; Amsterdam: 2010.
37. McDermott, AM. Defense mechanisms of tears and ocular surface. In: Dartt, DA., editor. *Encyclopedia of the Eye.* Elsevier; Amsterdam: 2010.
38. Tan KO, Sack RA, Holden BA, Swarbrick HA. Temporal sequence of changes in tear film composition during sleep. *Curr Eye Res.* 1993; 12:1001–1007. [PubMed: 8306709]

39. Zhou L, Huang LQ, Beuerman RW, Grigg ME, Li SF, Chew FT, Ang L, Stern ME, Tan D. Proteomic analysis of human tears: defensin expression after ocular surface surgery. *J Proteome Res.* 2004; 3:410–416. [PubMed: 15253421]
40. You Y, Fitzgerald A, Cozzi PJ, Zhao Z, Graham P, Russell PJ, Walsh BJ, Willcox M, Zhong L, Wasinger V, Li Y. Post-translation modification of proteins in tears. *Electrophoresis.* 2010; 31:1853–1861. [PubMed: 20506419]
41. Haynes RJ, McElveen JE, Dua HS, Tighe PJ, Liversidge J. Expression of human beta-defensins in intraocular tissues. *Invest Ophthalmol Vis Sci.* 2000; 41:3026–31. [PubMed: 10967060]
42. Paulsen FP, Pufe T, Schaudig U, Held-Feindt J, Lehmann J, Schroder JM, Tillmann BN. Detection of natural peptide antibiotics in human nasolacrimal ducts. *Invest Ophthalmol Vis Sci.* 2001; 42:2157–2163. [PubMed: 11527925]
43. Stoeckelhuber M, Messmer EM, Schubert C, Stoeckelhuber BM, Koehler C, Welsch U, Bals R. Immunolocalization of defensins and cathelicidin in human glands of Moll. *Ann Anat.* 2008; 190:230–237. [PubMed: 18396392]
44. Stoeckelhuber M, Stoeckelhuber BM, Welsch U. Apocrine glands in the eyelids of primates contribute to the ocular host defense. *Cells Tissues Organs.* 2004; 176:187–194. [PubMed: 15118398]
45. Yasui T, Tsukise A, Nara T, Kuwahara Y, Meyer W. Morphological, histochemical and immunohistochemical characterization of secretory production of the ciliary glands in the porcine eyelid. *Eur J Histochem.* 2006; 50:99–108. [PubMed: 16864120]
46. McDermott AM. The role of antimicrobial peptides at the ocular surface. *Ophthalmic Res.* 2009; 41:60–75. [PubMed: 19122467]
47. Pachigolla G, Blomquist P, Cavanagh HD. Microbial keratitis pathogens and antibiotic susceptibilities: a 5-year review of cases at an urban county hospital in north Texas. *Eye Contact Lens.* 2007; 33:45–49. [PubMed: 17224678]
48. Green M, Apel A, Stapleton F. Risk factors and causative organisms in microbial keratitis. *Cornea.* 2008; 27:22–27. [PubMed: 18245962]
49. Oren A, Ganz T, Liu L, Meerloo T. In human epidermis, β -defensin 2 is packaged in lamellar bodies. *Exp Mol Pathol.* 2003; 74:180–182. [PubMed: 12710950]
50. Braff MH, Di Nardo A, Gallo RL. Keratinocytes store the antimicrobial peptide cathelicidin in lamellar bodies. *J Invest Dermatol.* 2005; 124:394–400. [PubMed: 15675959]
51. Huang LC, Redfern RL, Narayanan S, Reins RY, McDermott AM. In vitro activity of human beta-defensin 2 against *Pseudomonas aeruginosa* in the presence of tear fluid. *Antimicrob Agents Chemother.* 2007; 51:3853–3860. [PubMed: 17724155]
52. Singh PK, Tack BF, McCray PB Jr, Welsh MJ. Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. *Am J Physiol Lung Cell Mol Physiol.* 2000; 279:L799–L805. [PubMed: 11053013]
53. Nagaoka I, Hirota S, Yomogida S, Ohwada A, Hirata M. Synergistic actions of antibacterial neutrophil defensins and cathelicidins. *Inflamm Res.* 2000; 49:73–79. [PubMed: 10738945]
54. Chen X, Niyonsaba F, Ushio H, Okuda D, Nagaoka I, Ikeda S, Okumura K, Ogawa H. Synergistic effect of antibacterial agents human beta-defensins, cathelicidin LL-37 and lysozyme against *Staphylococcus aureus* and *Escherichia coli*. *J Dermatol Sci.* 2005; 40:123–132. [PubMed: 15963694]
55. Kumar A, Hazlett LD, Yu FS. Flagellin suppresses the inflammatory response and enhances bacterial clearance in a murine model of *Pseudomonas aeruginosa* keratitis. *Infect Immun.* 2008; 76:89–96. [PubMed: 17938214]
56. Augustin DK, Heimer SR, Tan C, Li WY, Le Due JM, Evans DJ, Fleiszig SM. role of defensins in corneal epithelial barrier function against *P. aeruginosa* traversal. *Infect Immun.* 2011 In press.
57. Liesegang TJ, Melton LJ, Daly PJ, Ilstrup DM. Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982. *Arch Ophthalmol.* 1989; 107:1155–1159. [PubMed: 2787981]
58. Daher KA, Selsted ME, Lehrer RI. Direct inactivation of viruses by human granulocyte defensins. *J Virol.* 1986; 60:1068–1074. [PubMed: 3023659]

59. Bastian A, Schafer H. Human alpha-defensin 1 (HNP-1) inhibits adenoviral infection in vitro. *Regul Pept.* 2001; 101:157–161. [PubMed: 11495691]
60. Liesegang TJ, Forster RK. Spectrum of microbial keratitis in south Florida. *Am J Ophthalmol.* 1980; 90:38–47. [PubMed: 7395957]
61. Ritterband DC, Seedor JA, Shah MK, Koplin RS, McCormick SA. Fungal keratitis at the new york eye and ear infirmary. *Cornea.* 2006; 25:264–267. [PubMed: 16633023]
62. Sirikul T, Prabritputaloong T, Smathivat A, Chuck RS, Vongthongsri A. Predisposing factors and etiologic diagnosis of ulcerative keratitis. *Cornea.* 2008; 27:283–287. [PubMed: 18362653]
63. Gopinathan U, Sharma S, Garg P, Rao GN. Review of epidemiological features, microbiological diagnosis and treatment outcome of microbial keratitis: experience of over a decade. *Indian J Ophthalmol.* 2009; 57:273–279. [PubMed: 19574694]
64. Tanure MA, Cohen EJ, Sudesh S, Rapuano CJ, Laibson PR. Spectrum of fungal keratitis at Wills Eye Hospital, Philadelphia, Pennsylvania. *Cornea.* 2000; 19:307–312. [PubMed: 10832689]
65. Thew MR, Todd B. Fungal keratitis in far north Queensland, Australia. *Clin Experiment Ophthalmol.* 2008; 36:721–724. [PubMed: 19128375]
66. Xie L, Zhai H, Zhao J, Sun S, Shi W, Dong X. Antifungal susceptibility for common pathogens of fungal keratitis in Shandong Province, China. *Am J Ophthalmol.* 2008; 146:260–265. [PubMed: 18547535]
67. Perez-Balbuena AL, Vanzini-Rosano V, Valadez-Virgen J, Campos-Möller X. *Fusarium* keratitis in Mexico. *Cornea.* 2009; 28:626–630. [PubMed: 19512910]
68. Furlanetto RL, Andreo EG, Finotti IG, Arcieri ES, Ferreira MA, Rocha FJ. Epidemiology and etiologic diagnosis of infectious keratitis in Uberlandia, Brazil. *Eur J Ophthalmol.* 2010; 20:498–503. [PubMed: 20175055]
69. Lehrer RI, Ganz T, Szklarek D, Selsted ME. Modulation of the in vitro candidacidal activity of human neutrophil defensins by target cell metabolism and divalent cations. *J Clin Invest.* 1998; 81:1829–35. [PubMed: 3290255]
70. Wilde CG, Griffith JE, Marra MN, Snable JL, Scott RW. Purification and characterization of human neutrophil peptide 4, a novel member of the defensin family. *J Biol Chem.* 1989; 264:11200–11203. [PubMed: 2500436]
71. Raj PA, Antonyraj KJ, Karunakaran T. Large-scale synthesis and functional elements for the antimicrobial activity of defensins. *Biochem J.* 2000; 347:633–641. [PubMed: 10769165]
72. Harder J, Bartels J, Christophers E, Schroder JM. Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. *J Biol Chem.* 2001; 276:5707–5713. [PubMed: 11085990]
73. Hoover DM, Wu Z, Tucker K, Lu W, Lubkowski J. Antimicrobial characterization of human beta-defensin 3 derivatives. *Antimicrob Agents Chemother.* 2003; 47:2804–2809. [PubMed: 12936977]
74. López-García B, Lee PH, Yamasaki K, Gallo RL. Anti-fungal activity of cathelicidins and their potential role in *Candida albicans* skin infection. *J Invest Dermatol.* 2005; 125:108–115. [PubMed: 15982310]
75. den Hertog AL, van Marle J, van Veen HA, Van't Hof W, Bolscher JG, Veerman EC, Nieuw Amerongen AV. Candidacidal effects of two antimicrobial peptides: histatin 5 causes small membrane defects, but LL-37 causes massive disruption of the cell membrane. *Biochem J.* 2005; 388:689–695. [PubMed: 15707390]
76. Feng Z, Jiang B, Chandra J, Ghannoum M, Nelson S, Weinberg A. Human beta-defensins: Differential activity against Candidal species and regulation by *Candida albicans*. *J Dent Res.* 2005; 84:445–450. [PubMed: 15840781]
77. Kiehne K, Brunke G, Meyer D, Harder J, Herzig KH. Oesophageal defensin expression during *Candida* infection and reflux disease. *Scand J Gastroenterol.* 2005; 40:501–507. [PubMed: 16036501]
78. Ooi EH, Wormald P-J, Carney AS, James CL, Tan LW. Fungal allergens induce cathelicidin LL-37 expression in chronic rhinosinusitis patients in a nasal explant model. *Am J Rhinol.* 2007; 21:367–372. [PubMed: 17621825]

79. Krishnakumari V, Rangaraj N, Nagaraj R. Antifungal activities of human beta-defensins HBD-1 to HBD-3 and their C-terminal analogs Phd1 to Phd3. *Antimicrob Agents Chemother*. 2009; 53:256–260. [PubMed: 18809937]
80. Alekseeva L, Huat D, Femenia F, Mouyna I, Abdelouahab M, Cagna A, Guerrier D, Tichanné-Seltzer V, Baeza-Squiban A, Chermette R, Latgé JP, Berkova N. Inducible expression of beta defensins by human respiratory epithelial cells exposed to *Aspergillus fumigatus* organisms. *BMC Microbiol*. 2009; 9:33. [PubMed: 19208266]
81. Steubesand N, Kiehne K, Brunke G, Pahl R, Reiss K, Herzig KH, Schubert S, Schreiber S, Fölsch UR, Rosenstiel P, Arlt A. The expression of the beta-defensins hBD-2 and hBD-3 is differentially regulated by NFkB and MAPK/AP-1 pathways in an in vitro model of *Candida* esophagitis. *BMC Immunol*. 2009; 10:36. [PubMed: 19523197]
82. Bahri R, Saidane-Mosbahi D, Rouabhia M. *Candida famata* modulates toll-like receptor, beta-defensin, and proinflammatory cytokine expression by normal human epithelial cells. *J Cell Physiol*. 2010; 222:209–218. [PubMed: 19780045]
83. Bahri R, Curt S, Saidane-Mosbahi D, Rouabhia M. Normal human gingival epithelial cells sense *C. parapsilosis* by toll-like receptors and modulate its pathogenesis through antimicrobial peptides and proinflammatory cytokines. *Mediators Inflamm*. 2010; 2010:940383. Epub May 3. [PubMed: 20454633]
84. Yuan X, Hua X, Wilhelmus KR. The corneal expression of antimicrobial peptides during experimental fungal keratitis. *Curr Eye Res*. 2010; 35:872–879. [PubMed: 20858107]
85. Gao N, Kumar A, Guo H, Wu X, Wheeler M, Yu F-S. Topical flagellin mediated innate defence against *Candida albicans* keratitis. *Invest Ophthalmol Vis Sci*. 2011 In press.
86. Tu EY, Joslin CE. Recent outbreaks of atypical contact lens-related keratitis: what have we learned? *Am J Ophthalmol*. 2010; 150:602–608. [PubMed: 21036209]
87. Schuster FL, Jacobs LS. Effects of magainins on ameba and cyst stages of *Acanthamoeba polyphaga*. *Antimicrob Agents Chemother*. 1992; 36:1263–1271. [PubMed: 1416825]
88. Otri AM, Mohammed I, Abedin A, Cao Z, Hopkinson A, Panjwani N, Dua HS. Antimicrobial peptides expression by ocular surface cells in response to *Acanthamoeba castellanii*: an in vitro study. *Br J Ophthalmol*. 2010; 94:1523–1527. [PubMed: 20679078]
89. Maltseva IA, Fleiszig SM, Evans DJ, Kerr S, Sidhu SS, McNamara NA, Basbaum C. Exposure of human corneal epithelial cells to contact lenses in vitro suppresses the upregulation of human beta-defensin-2 in response to antigens of *Pseudomonas aeruginosa*. *Exp Eye Res*. 2007; 85:142–153. [PubMed: 17531223]
90. Linzmeier RM, Ganz T. Human defensin gene copy number polymorphisms: comprehensive analysis of independent variation in alpha- and beta-defensin regions at 8p22-p23. *Genomics*. 2005; 86:423–430. [PubMed: 16039093]
91. Hollox EJ. Copy number variation of beta-defensins and relevance to disease. *Cytogenet Genome Res*. 2008; 123:148–155. [PubMed: 19287149]
92. Milanese M, Segat L, Arraes LC, Garzino-Demo A, Crovella S. Copy number variation of defensin genes and HIV infection in Brazilian children. *J Acquir Immune Defic Syndr*. 2009; 50:331–333. [PubMed: 19194307]
93. Carter J, Churchill AJ, Gorman C, Haynes R. A case of bilateral endophthalmitis and carriage of beta-defensin 1 44CC genotype. *Br J Ophthalmol*. 2007; 91:1249–1250. [PubMed: 17709589]
94. Carter JG, West SK, Painter S, Haynes RJ, Churchill AJ. β -Defensin 1 haplotype associated with postoperative endophthalmitis. 2010; 88:786–790.
95. Brewitt H, Sistani F. Dry eye disease: the scale of the problem. *Surv Ophthalmol*. 2001; 45(s2):S199. [PubMed: 11587143]
96. Gilbard JP, Farris RL, Santamaria J III. Osmolarity of tear microvolumes in keratoconjunctivitis sicca. *Arch Ophthalmol*. 1978; 96:677–681. [PubMed: 646697]
97. Farris RL. Tear osmolarity – a new gold standard? *Adv Exp Med Biol*. 1994; 350:495–503. [PubMed: 8030524]
98. Afonso AA, O'Brien L, Monroy DC, Selzer M, Lokeshwar B, Pflugfelder SC. tear fluid gelatinase B activity correlates with IL-alpha concentrations and fluorescein clearance in ocular rosacea. *Invest Ophthalmol Vis Sci*. 1999; 40:2506–2512. [PubMed: 10509643]

99. Pflugfelder SC, Jones D, Ji Z, Afonso A, Monroy D. Altered cytokine balance in tear fluid and conjunctiva of patients with Sjogren's syndrome keratoconjunctivitis sicca. *Curr Eye Res.* 1999; 19:201–211. [PubMed: 10487957]
100. Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. *Invest Ophthalmol Vis Sci.* 2001; 41:2283–2292. [PubMed: 11527941]
101. Bron AJ, Tiffany JM, Yokoi N, Gouveia SM. Using osmolarity to diagnose dry eye: a compartmental hypothesis and review of our assumptions. *Ave Exp Med Biol.* 2002; 506:1087–1095.
102. Kawasaki S, Kawamoto S, Yokoi N, Connon C, Minesaki Y, Kinoshita S, Okubo K. Up-regulated gene expression in the conjunctival epithelium of patients with Sjogren's syndrome. *Exp Eye Res.* 2003; 77:17–26. [PubMed: 12823984]
103. Narayanan S, Manning J, Proske R, McDermott AM. Effect of hyperosmolality on beta-defensin gene expression by human corneal epithelial cells. *Cornea.* 2006; 25:1063–1068. [PubMed: 17133055]
104. Vivino FB, Minerva P, Huang CH, Orlin SE. Corneal melt as the initial presentation of primary Sjogren's syndrome. *J Rheumatol.* 2001; 28:379–382. [PubMed: 11246683]
105. Stern ME, Gao J, Schwalb TA, Ngo M, Tieu D, Chan CC, Reis BL, Whitcup SM, Thompson D, Smith JA. Conjunctival T-cell subpopulations in Sjogren's and no-Sjogren's patients with dry eye. *Invest Ophthalmol Vis Sci.* 2002; 43:2609–2614. [PubMed: 12147592]
106. Hida RY, Ohashi Y, Takano Y, Dogru M, Goto E, Fujishima H, Saito I, Saito K, Fukase Y, Tsubota K. Elevated levels of human α -defensin in tears of patients with allergic conjunctival disease complicated by corneal lesions: detection by SELDI protein chip systems and quantification. *Curr Eye Res.* 2005; 30:723–730. [PubMed: 16123017]
107. Ikeda A, Nakanishi Y, Sakimoto T, Shoji J, Sawa M, Nemoto N. Expression of β defensins in ocular surface tissue of experimentally developed allergic conjunctivitis mouse model. *Jpn J Ophthalmol.* 2006; 50:106.
108. Larrick JW, Morgan JG, Palings I, Hirata M, Yen MH. Complementary DNA sequence of rabbit CAP18 – a unique lipopolysaccharide binding protein. *Biochem Biophys Res Commun.* 1991; 179:170–175. [PubMed: 1883348]
109. Larrick J, Hirata M, Balint R, Lee J, Zhong J, Wright SC. Human CAP 18: a novel antimicrobial lipopolysaccharide-binding protein. *Infect Immun.* 1995; 63:1291–1297. [PubMed: 7890387]
110. Ohgami K, Ilieva IB, Shiratori K, Isogai E, Yoshida K, Kotake S, Nishida T, Mizuki N, Ohno S. Effect of human cationic antimicrobial peptide protein 18 peptide on endotoxin-induced uveitis in rats. *Invest Ophthalmol Vis Sci.* 2003; 44:4412–4418. [PubMed: 14507887]
111. Jager K, Garreis F, Posa A, Dunse M, Paulsen FP. Functional relationship between cationic amino acid transporters and beta-defensins: implications for dry skin diseases and the dry eye. *Ann Anat.* 2010; 192:65–69. [PubMed: 20307963]
112. Jager K, Bonisch U, Risch M, Worlitzsch D, Paulsen F. Detection and regulation of cationic amino acid transporters in healthy and diseased ocular surface. *Invest Ophthalmol Vis Sci.* 2009; 50:1112–1121. [PubMed: 18997084]
113. Befus AD, Mowat C, Gilchrist M, Hu J, Solomon S, Bateman A. Neutrophil defensins induce histamine secretion from mast cells: mechanisms of action. *J Immunol.* 1999; 163:947–953. [PubMed: 10395691]
114. Niyonsaba F, Someya A, Hirata M, Ogawa H, Nagaoka I. Evaluation of the effects of peptide antibiotics human beta-defensins-1/-2 and LL-37 on histamine release and prostaglandin D(2) production from mast cells. *Eur J Immunol.* 2001; 31:1066–1075. [PubMed: 11298331]
115. van Wetering S, Mannesse-Lazeroms SPG, van Sterkenburg MA, Daha MR, Dijkman JH, Hiemstra PS. Effect of defensins on interleukin-8 synthesis in airway epithelial cells. *Am J Physiol.* 1997; 272:L888–896. [PubMed: 9176253]
116. van Wetering S, Mannesse-Lazeroms SPG, van Sterkenburg MA, Hiemstra PS. Neutrophil defensins stimulate the release of cytokines by airway epithelial cells: modulation by dexamethasone. *Inflamm Res.* 2002; 51:8–15. [PubMed: 11852911]

117. Tjabringa GS, Aarbiou J, Ninaber DK, Drijfhout JW, Sorensen OE, Borregaard N, Rabe KF, Hiemstra PS. The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. *J Immunol.* 2003; 171:6690–6696. [PubMed: 14662872]
118. Niyonsaba F, Ushio H, Nagaoka I, Okumura K, Ogawa H. The human beta-defensins (-1, -2, -3, -4) and cathelicidin LL-37 induce IL-18 secretion through p38 and ERK MAPK activation in primary human keratinocytes. *J Immunol.* 2005; 175:1776–1784. [PubMed: 16034119]
119. Garcia JR, Jaumann F, Schulz S, Krause A, Rodriguez-Jimenez J, Forssmann U, Adermann K, Kluver E, Vogelmeier C, Becker D, Hedrich R, Forssmann WG, Bals R. Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of *Xenopus* oocytes and the induction of macrophage chemoattraction. *Cell Tissue Res.* 2001; 306:257–264. [PubMed: 11702237]
120. Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J, Anderson M, Schroder JM, Wang JM, Howard OM, Oppenheim JJ. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. *Science.* 1999; 286:525–528. [PubMed: 10521347]
121. De Yang, Chen Q, Schmidt AP, Andersin GM, Wang JM, Wooters J, Oppenheim JJ, Chertov O. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL-1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes and T cells. *J Exp Med.* 2000; 192:1069–1074. [PubMed: 11015447]
122. Kurpakus-Wheater M, Kernacki KA, Hazlett LD. Maintaining corneal integrity. How the “window” stays clear. *Progr Histochem Cytochem.* 2001; 3:179–259.
123. McDermott AM, Redfern RL, Zhang B. Human β -defensin 2 is up-regulated during re-epithelialization of the cornea. *Curr Eye Res.* 2001; 22:64–67. [PubMed: 11402380]
124. Yin J, Yu FS. LL-37 promotes high glucose-attenuated epithelial wound healing via EGFR transactivation in organ cultured corneas. *Invest Ophthalmol Vis Sci.* 2010; 51:1891–1897. [PubMed: 19797203]
125. Li J, Raghunath M, Tan D, Lareu RR, Chen ZC, Beuerman RW. Defensins HNP1 and HBD2 stimulation of wound-associated responses in human conjunctival fibroblasts. *Invest Ophthalmol Vis Sci.* 2006; 47:3811–3819. [PubMed: 16936092]
126. Li J, Zhu HY, Beuerman RW. Stimulation of specific cytokines in human conjunctival epithelial cells by defensins HNP1, HBD-2 and HBD-3. *Invest Ophthalmol Vis Sci.* 2009; 50:644–653. [PubMed: 18806299]
127. Koczulla R, von Degenfeld G, Kupatt C, Krotz F, Zahler S, Gloe T, Issbrucker K, Unterberger P, Zaiou M, Lebherz C, Karl A, Raake P, Pfosser A, Boekstegers P, Welsch U, Heimstra PS, Vogelmeier C, Gallo RL, Clauss M, Bals R. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. *J Clin Invest.* 2003; 111:1665–1672. [PubMed: 12782669]
128. Chavakis T, Cines DB, Rhee JS, Liang OD, Schubert U, Hammes HP, Higazi AA, Nawroth PP, Preissner KT, Bdeir K. Regulation of neovascularisation by human neutrophil peptides (alpha-defensins): a link between inflammation and angiogenesis. *FASEB J.* 2004; 18:1306–1308. [PubMed: 15208269]
129. Economopoulou M, Bdeir K, Cines DB, Fogt F, Bdeir Y, Lubkowski J, Lu W, Preissner KT, Hammes HP, Chavakis T. Inhibition of pathologic retinal neovascularisation by alpha-defensins. *Blood.* 2005; 106:3831–3838. [PubMed: 16123222]
130. Hanckock RE, Sahl HG. Antimicrobial and host-defence peptides as new anti-infective therapeutic strategies. *Nat Biotechnol.* 2006; 24:1551–1557. [PubMed: 17160061]
131. Nos-Barbera S, Portoles M, Morilla A, Ubach J, Andreu D, Paterson CA. Effect of hybrid peptides of cecropin A and melittin in an experimental model of bacterial keratitis. *Cornea.* 1997; 16:101–106. [PubMed: 8985641]
132. Brandt CR, Akkarawongsa R, Altmann S, Jose G, Kolb AW, Waring AJ, Lehrer RI. Evaluation of a theta-defensin in a murine model of herpes simplex virus type 1 keratitis. *Invest Ophthalmol Vis Sci.* 2007; 48:5118–5124. [PubMed: 17962464]
133. Mannis M. The use of antimicrobial peptides in ophthalmology: an experimental study in corneal preservation and the management of bacterial keratitis. *Trans Am Ophthalmol Soc.* 2002; 100:243–271. [PubMed: 12545697]

134. McDermott AM, Rich D, Cullor J, Mannis MJ, Smith W, Reid T, Murphy CJ. The in vitro activity of selected defensins against an isolate of *Pseudomonas* in the presence of human tears. *Br J Ophthalmol*. 2006; 90:609–611. [PubMed: 16622092]
135. Huang LC, Jean D, McDermott AM. Effect of preservative free artificial tears on the antimicrobial activity of human beta-defensin-2 and cathelicidin LL-37 in vitro. *Eye Contact Lens*. 2005; 31:34–38. [PubMed: 15665670]
136. Liu S, Zhou L, Li J, Suresh A, Verma C, Foo YH, Yap EP, Tan DT, Beuerman RW. Linear analogues of human beta-defensin 3: concepts for design of antimicrobial peptides with reduced toxicity to mammalian cells. *Chembiochem*. 2008; 9:964–973. [PubMed: 18350527]
137. Zhou L, Liu SP, Chen LY, Li J, Ong LB, Guo L, Wohland T, Tang CC, Lakshminarayanan R, Mavinahalli J, Verma C, Beuerman RW. The structural parameters for antimicrobial activity, human epithelial cell cytotoxicity and killing mechanism of synthetic monomer and dimer analogues derived from hBD-3 C-terminal region. *Amino Acids*. 2011; 40:123–133. [PubMed: 20397033]
138. Liu SP, Zhou L, Lakshminarayanan R, Beuerman RW. Multivalent antimicrobial peptides as therapeutics: design principles and structural diversities. *Int J Pept Res Ther*. 2010; 16:199–213. [PubMed: 20835389]
139. Kumar A, Kolar SS, Zao M, McDermott AM, Cai C. Localization of antimicrobial peptides on polymerized liposomes leading to their enhanced efficacy against *Pseudomonas aeruginosa*. *Mol BioSyst*. 2011 In press.
140. Schwab IR, Dries D, Cullor J, Smith W, Mannis M, Reid T, Murphy CJ. Corneal storage medium preservation with defensins. *Cornea*. 1992; 11:370–375. [PubMed: 1424662]
141. McAnulty JF, Reid TW, Waller KR, Murphy CJ. Successful six-day kidney preservation using trophic factor supplemented media and simple cold storage. *Am J Transplant*. 2002; 2:712–718. [PubMed: 12243492]
142. Sousa LB, Mannis MJ, Schwab IR, Cullor J, Hosotani H, Smith W, Jaynes J. The use of synthetic cecropin (D5C) in disinfecting contact lens solutions. *CLAO J*. 1996; 22:114–117. [PubMed: 8728617]
143. Mathews SM, Spallholz JE, Grimson MJ, Dubielzig RR, Gray T, Reid TW. Prevention of bacterial colonization of contact lenses with covalently attached selenium and effects on the rabbit cornea. *Cornea*. 2006; 25:806–814. [PubMed: 17068458]
144. Zhu H, Kumar A, Ozkan J, Bandara R, Ding A, Perera I, Steinberg P, Kumar N, Lao W, Griesser SS, Britcher L, Griesser HJ, Willcox MD. Fimbricide-coated antimicrobial lenses: their in vitro and in vivo effects. *Optom Vis Sci*. 2008; 85:292–300. [PubMed: 18451734]
145. Willcox MD, Hume EB, Aliwarga Y, Kumar N, Cole N. A novel cationic-peptide coating for the prevention of microbial colonization on contact lenses. *J Appl Microbiol*. 2008; 105:1817–1825. [PubMed: 19016975]
146. Cole N, Human EB, Vijay AK, Sankaridurg P, Kumar N, Willcox MD. In vivo performance of melamine as an antimicrobial coating for contact lenses in models of CLARE and CLPU. *Invest Ophthalmol Vis Sci*. 2010; 51:390–395. [PubMed: 19710414]

Figure 1.

Expression profile of host-defence peptides in the eye The diagram summarizes the pattern of expression of the major HDPs in the human eye. These data are derived primarily from studies to detect peptide expression that have been performed on cultured cells *in vitro* and on tissue/tear fluid samples from human donors (these studies are summarized and references given in section 1). Lacrimal gland and lacrimal drainage are not included but are discussed in section 1.3.